* Cardlytics Inc CDLX.OQ CDLX.O is expected to show a
rise in
quarterly revenue when it reports results on May 8 for the
period ending March 31 2024
* The Atlanta Georgia-based company is expected to report a
11.4% increase in revenue to $71.693 million from $64.33 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.The company's guidance on March 14 2024, for
the period ended March 31, was for revenue between $70.00
million and $73.00 million.
* LSEG's mean analyst estimate for Cardlytics Inc is for a
loss
of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cardlytics
Inc is
$18.00, above its last closing price of $15.20.
The company's guidance on March 14 2024 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between 70 million and 1 million (USD).
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.15 0.12 0.14 Beat 16.7
Sep. 30 2023 -0.01 -0.01 0.01 Beat 200
Jun. 30 2023 -0.35 -0.35 -0.24 Beat 32.1
Mar. 31 2023 -0.56 -0.56 -0.25 Beat 55.7
Dec. -0.46 -0.46 -0.29 Beat 37.5
31 2022
Sep. 30 2022 -0.50 -0.57 -0.50 Beat 12.3
Jun. 30 2022 -0.42 -0.47 -0.65 Missed -38.9
Mar. 31 2022 -0.52 -0.55 -0.38 Beat 31.3
This summary was machine generated May 7 at 02:31 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)